CARE

Cavernomas A Randomised Effectiveness (CARE) pilot trial, to address the effectiveness of active treatment (with neurosurgery or stereotactic radiosurgery) versus conservative management in people with symptomatic brain cavernoma

The pros and cons of medical management versus medical and surgical management are finely balanced. The most reliable way of finding out which management is best is to do a randomised trial, in which suitable patients are allocated to medical management or medical and surgical management at random. This has never been done with cavernomas, and this was the top priority identified by a Priority Setting Partnership for cavernoma.

care logo

Chief Investigator: Prof Rustam Al-Shahi Salman

Number and location of participating sites (by region/ country): 42 sites - UK and Republic of Ireland

EudraCT number: n/a

ISRCTN number: 41647111

 

Funder: National Institute for Health Research Health Technology Assessment programme

Start and End date

Of grant award: September 2020

Of recruitment: April 2023

Current Status: Completed

Trial Website: The Care Study

Email: care.trial@ed.ac.uk

 

UK GDPR Privacy Statement: As part of the PIS

 

Sponsor: Accord, https://www.accord.scot/

 

Chief Investigator:

Prof Rustam Al-Shahi Salman, CCBS, Chancellor’s Building, 49 Little France Crescent, Edinburgh EH16 4SB

Trial Manager:

Dr Laura Forsyth, Edinburgh Clinical Trials Unit, Usher Building, The University of Edinburgh, 5‒7 Little France Road, Edinburgh BioQuarter ‒ Gate 3 EDINBURGH EH16 4UX

 

ECTU involvement: Trial Management, Statistics, Health Economics, Database and randomisation service

This article was published on